Starting a GLP-1 medication raises many questions, and how it interacts with your thyroid is one that deserves a clear answer. Here is what the evidence actually shows and what you should monitor during treatment.
Learn about the relationship between GLP-1 medications and thyroid function, what research shows, and how to monitor your treatment safely.
What research says about thyroid and GLP-1
GLP-1 receptor agonists like semaglutide and tirzepatide work mainly through appetite control and blood sugar regulation. Clinical studies have shown that these medications can be associated with changes in thyroid hormone levels in some people, particularly those with a predisposition to thyroid disease.
Research published in the New England Journal of Medicine and the Journal of Clinical Endocrinology & Metabolism indicated a small but measurable risk of thyroid tumors in rodents exposed to high doses of GLP-1. In humans, data remain limited, but regulatory agencies like the FDA include a warning on these medications for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2.
This does not mean everyone using GLP-1 will develop thyroid problems. It means that monitoring is part of responsible treatment.
Track the estimated level of each dose and know the right time to inject.
See it in the appWhat you may notice in practice
In day-to-day use, some people report changes in energy levels, weight, and even symptoms that resemble thyroid issues during GLP-1 treatment. Most of these reports are individual observations rather than robust scientific evidence. What is known is that GLP-1 does not treat the thyroid directly, but it can indirectly influence metabolism in ways some people perceive as changes.
When the body responds to treatment with significant weight loss, thyroid hormones may shift as a reflection of that change. The same thing happens with weight loss from other causes: the hypothalamic-pituitary-thyroid axis adapts.
